
SPRUCE BIOSCIENCES, INC. — Investor Relations & Filings
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for serious, underserved neurological disorders. The company's mission is to advance targeted, first-in-class treatments to address significant unmet medical needs. Its lead investigational therapy, TA-ERT, is being advanced for conditions such as MPS IIIB (Sanfilippo Syndrome Type B), a rare and progressive neurological disease. Guided by a patient-centric approach, Spruce Biosciences aims to develop transformative therapies that offer meaningful outcomes beyond conventional approaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-26 | English | |
| 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-05-13 | English | |
| 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-21 | English | |
| 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-20 | English | |
| ARS - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | |
| DEF 14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47072046 | 8-K | 2026-05-26 | English | ||
| 45579664 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-05-13 | English | ||
| 34943609 | 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-21 | English | ||
| 34693721 | 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-20 | English | ||
| 33939629 | ARS - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | ||
| 33939247 | DEF 14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | ||
| 33002588 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-03-20 | English | ||
| 31294669 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31294663 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31294647 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31294682 | SCHEDULE 13G Filing | 2026-02-10 | English | ||
| 32896600 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-02-05 | English | ||
| 31294656 | 4 Filing | 2026-01-21 | English | ||
| 12983899 | 8-K | 2026-01-08 | English | ||
| 12983900 | Director's Dealing 2026 | 2026-01-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
|
APURES CO., LTD.
Biotech firm providing MICROPIG models, bio-resources, and …
|
149300 | KR | Professional, scientific and te… |
|
Aran Research & Development (1982) Ltd.
A product design and development firm providing services fr…
|
ARAN | IL | Professional, scientific and te… |
|
Arch Biopartners Inc.
Developing novel drugs for acute kidney injury (AKI) and ch…
|
ARCH | CA | Professional, scientific and te… |
|
ARCHER MATERIALS LIMITED
Develops semiconductor devices for quantum computing and me…
|
AXE | AU | Professional, scientific and te… |
|
ARGENICA THERAPEUTICS LIMITED
Clinical-stage developer of neuroprotective drugs for acute…
|
AGN | AU | Professional, scientific and te… |
|
ARIUS Research Inc.
Discovery and development of targeted antibody therapeutics…
|
ARI | CA | Professional, scientific and te… |
|
AROVELLA THERAPEUTICS LIMITED
Develops off-the-shelf iNKT cell therapies for blood cancer…
|
ALA | AU | Professional, scientific and te… |
|
Artiva Biotherapeutics, Inc.
Develops allogeneic, off-the-shelf NK cell therapies for ca…
|
ARTV | US | Professional, scientific and te… |
|
ARVINAS, INC.
Clinical-stage biopharma developing therapeutics based on t…
|
ARVN | US | Professional, scientific and te… |
SPRUCE BIOSCIENCES, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35408/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35408 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35408 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35408 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35408}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SPRUCE BIOSCIENCES, INC. (id: 35408)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.